{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T10:48:57Z","timestamp":1775558937580,"version":"3.50.1"},"reference-count":31,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Skin Pharmacol Physiol"],"published-print":{"date-parts":[[2014]]},"abstract":"<jats:p>Actinic keratosis, a frequent carcinoma in situ of non-melanoma skin cancer (NMSC), can transform into life-threatening cutaneous squamous cell carcinoma. Current treatment is limited due to low complete clearance rates and asks for novel therapeutic concepts; the novel purine nucleotide analogue OxBu may be an option. In order to enhance skin penetration, solid lipid nanoparticles (SLN, 136-156 nm) were produced with an OxBu entrapment efficiency of 96.5 \u00b1 0.1%. For improved preclinical evaluation, we combined tissue engineering with clinically used keratin-18 quantification. Three doses of 10&lt;sup&gt;-3&lt;\/sup&gt; mol\/l OxBu, dissolved in phosphate-buffered saline as well as loaded to SLN, were effective on reconstructed NMSC. Tumour response and apoptosis induction were evaluated by an increase in caspase-cleaved fragment of keratin-18, caspase-7 activation as well as by reduced expression of matrix metallopeptidase-2 and Ki-67. OxBu efficacy was superior to equimolar 5-fluorouracil solution, and thus the drug should be subjected to the next step in preclinical evaluation.<\/jats:p>","DOI":"10.1159\/000354118","type":"journal-article","created":{"date-parts":[[2014,2,5]],"date-time":"2014-02-05T07:47:43Z","timestamp":1391586463000},"page":"173-173","source":"Crossref","is-referenced-by-count":9,"title":["Improving Topical Non-Melanoma Skin Cancer Treatment: In vitro Efficacy of a Novel Guanosine-Analog Phosphonate"],"prefix":"10.1159","volume":"27","author":[{"given":"C.","family":"Ali-von Laue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Zoschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Lehnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"K\u00fcchler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Mehnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Blaschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.D.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Plendl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Weindl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.C.","family":"Korting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Hoeller Obrigkeit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-F.","family":"Merk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sch\u00e4fer-Korting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2014,2,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-4632.2007.03060.x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.transproceed.2010.08.003"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jaad.2009.06.020"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2133.2010.09873.x"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa1111170"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080%2F14756360701433414"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3109%2F14756366.2010.503609"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ijpharm.2010.06.036"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1289%2Fehp.1104782"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093%2Fannonc%2Fmdr451"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159%2F000257258"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002%2Fjps.21817"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jconrel.2005.09.052"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080%2F1061186021000038364"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007%2Fs11095-006-9225-9"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1034%2Fj.1600-0625.2001.100406.x"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1751-1097.2008.00432.x"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jconrel.2007.01.017"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016%2FS0939-6411%2898%2900074-5"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.addr.2007.04.003"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jconrel.2005.09.045"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002%2Fjps.2600510825"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111%2Fcas.12026"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182%2Fblood-2011-09-378356"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007%2Fs12032-013-0551-6"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.intimp.2009.02.004"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1158%2F1541-7786.MCR-11-0222"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1159%2F000324053"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jbiotec.2010.01.001"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ejpb.2009.03.009"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007%2Fs00403-009-1021-z"}],"container-title":["Skin Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/354118","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/354118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:41:47Z","timestamp":1745433707000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000354118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,5,1]]},"published-print":{"date-parts":[[2014,5,19]]}},"URL":"https:\/\/doi.org\/10.1159\/000354118","archive":["Portico"],"relation":{},"ISSN":["1660-5527","1660-5535"],"issn-type":[{"value":"1660-5527","type":"print"},{"value":"1660-5535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}